Accreditations and approvals Colibri Healthcare, LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Individual state nursing approvals Colibri Healthcare, LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. In addition to states that accept courses offered by ANCC Accredited Providers, Colibri Healthcare, LLC is an approved Provider of continuing education in nursing by: Alabama Board of Nursing, Provider #ABNP1418 (valid through February 5, 2025); Arkansas State Board of Nursing, Provider #50-4007; California Board of Registered Nursing, Provider #CEP17480 (valid through January 31, 2024); California Board of Vocational Nursing and Psychiatric Technicians (LVN Provider #V15058, PT Provider #V15020; valid through December 31, 2023); District of Columbia Board of
Nursing, Provider #50-4007; Florida Board of Nursing, Provider #50-4007; Georgia Board of Nursing, Provider #50-4007; Kentucky Board of Nursing, Provider #7-0076 (valid through December 31, 2023; CE Broker Provider #50-4007); Michigan Board of Nursing, Provider #50-4007; Mississippi Board of Nursing, Provider #50- 4007; New Mexico Board of Nursing, Provider #50-4007; North Dakota Board of Nursing, Provider #50-4007; South Carolina Board of Nursing, Provider #50-4007; and West Virginia Board of Registered Nurses, Provider #50-4007. This CE program satisfies the Massachusetts States Board’s regulatory requirements as defined in 244 CMR5.00: Continuing Education.
Activity director Deborah Martin, DNP, MBA, RN, NE-BC, FACHE, Director of Learning Innovation Colibri Healthcare, LLC Disclosures Resolution of conflict of interest
Sponsorship/commercial support and non-endorsement It is the policy of Colibri Healthcare, LLC not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.
In accordance with the ANCC Standards for Commercial Support for continuing education, Colibri Healthcare, LLC implemented mechanisms prior to the planning and implementation of the continuing education activity, to identify and resolve conflicts of interest for all individuals in a position to control content of the course activity. Disclaimer The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative
to diagnostic and treatment options of a specific patient’s medical condition.
©2023: All Rights Reserved. Materials may not be reproduced without the expressed written permission or consent of Colibri Healthcare, LLC. The materials presented in this course are meant to provide the consumer with general information on the topics covered. The information provided was prepared by professionals with practical knowledge of the areas covered. It is not meant to provide medical, legal, or professional advice. Colibri Healthcare, LLC recommends that you consult a medical, legal, or professional services expert licensed in your state. Colibri Healthcare, LLC has made all reasonable efforts to ensure that all content provided in this course is accurate and up to date at the time of printing, but does not represent or warrant that it will apply to your situation nor circumstances and assumes no liability from reliance on these materials. Quotes are collected from customer feedback surveys. The models are intended to be representative and not actual customers. Course verification All individuals involved have disclosed that they have no No. 241, every reasonable effort has been made to ensure that the content in this course is balanced and unbiased. significant financial or other conflicts of interest pertaining to this course. Likewise, and in compliance with California Assembly Bill
INTRODUCTION
Opioid use disorder (OUD) has reached epidemic proportions with substantial negative impacts on society. OUD is a chronic, relapsing disease influenced by genetics, stress response, and prior experimentation or exposure (Brown & Capili, 2020). Mu opioid receptors (MORs) modulate nociception, stress, temperature, respiration, endocrine activity, memory, mood, and motivation (Herman et al., 2022). MORs bind opioids, delta opioids, kappa opioids, and nociception receptors to increase drug tolerance. As a result, a physical dependence can develop with between 2 and 10 days of continuous use, with withdrawal symptoms occurring when use of the substance is stopped abruptly (Herman et al., 2022). Healthcare is provided to patients with many ailments in many healthcare settings. Patients might seek care for an acute illness or the worsening of a chronic condition. Often, pain is the leading reason for seeking medical care. Appropriate prescribing practices are critical for all medications, and drugs that are considered controlled substances require additional attention. The Drug Enforcement Agency (DEA), the Food and Drug Administration (FDA), and the U.S. Department of Health and Human Services (HHS) all have a role in determining the scheduling of prescription medications. Healthcare
providers must understand federal and state requirements for prescribing all controlled substances. In addition, inappropriate prescribing practices resulting in the misuse and/or abuse of opioids have led to many changes, including new safety and quality recommendations. Prescribing any medication must be performed with care while considering possible patient-specific risks. Prescribing controlled substances requires a heightened awareness for both patient and provider. Federal and state laws and regulations must be followed when prescribing controlled substances. Additionally, other issues, including the more widespread availability of medical marijuana and the opioid epidemic, have increased the complexity of the controlled substance prescribing process. All prescribers must be aware of federal and state laws regulating controlled substances. Prescribing opioid analgesics for acute and chronic pain has come under intense scrutiny as the opioid epidemic has worsened. In 2020, the HHS estimated that 10.1 million people misused prescription opioids. Opioid overdoses, prescription and illicit, accounted for 42,000 deaths; 40% involved a prescription opioid (HHS, 2021). Appropriately prescribing first- time opioid analgesics for acute pain is critical in preventing future opioid abuse (Goldstick et
EliteLearning.com/Nursing
Book Code: AUS3024
Page 69
Powered by FlippingBook